MCID: FLL037
MIFTS: 76

Follicular Lymphoma

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Follicular Lymphoma

MalaCards integrated aliases for Follicular Lymphoma:

Name: Follicular Lymphoma 37 12 72 49 36 28 14
Lymphoma, Follicular 49 41 69
Lymphoma Follicular 51

Classifications:



Summaries for Follicular Lymphoma

NIH Rare Diseases : 49 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 545Disease definitionFollicular lymphoma is a form of non-Hodgkin lymphoma (see this term) characterized by a proliferation of B cells whose nodular structure of follicular architecture is preserved.EpidemiologyPrevalence of follicular lymphoma is estimated at about 1/3,000.Clinical descriptionThe median age at diagnosis is 60-65 years. The disease is extremely rare in children. Follicular lymphoma is located primarily in the lymph nodes, but can also involve the spleen, bone marrow, peripheral blood and Waldeyer's ring. The skin and central nervous system are affected in rare cases. Symptoms appear at an advanced stage of the disease and can include fever, night sweats and weight loss. At diagnosis, patients usually present with adenopathy and, in 50% of cases, splenomegaly.EtiologyIn 85% of cases, follicular lymphomas are associated with a translocation t(14;18) (q32;q21), which activates the BCL2 gene encoding the BCL2 protein that is essential for some apoptosis processes.Diagnostic methodsDiagnosis is based on histological analysis of the adenopathy, a complete blood count, measurement of lactate dehydrogenase (LDH) and biopsy analysis of a lymph node. Examination using imagery (particularly a chest radiograph) is required. The observation of the translocation t(14;18) by polymerase chain reaction (PCR), in addition to suggested histological results, confirms the diagnosis.Differential diagnosisDifferential diagnoses include chronic lymphocytic B cell leukemia, diffuse large B cell lymphoma, mantle cell lymphoma and MALT lymphoma (see these terms).Management and treatmentIf the lymphoma is localized it should be treated by radiotherapy. In the case of advanced stage lymphoma, chemotherapy with immuno-chemotherapy should be offered (rituximab combined with CHOP). In cases of chemosensitive relapse, treatment can be intensified.PrognosisThe survival rate at five years is 80-90% and medial survival is approximately 10-12 years.Visit the Orphanet disease page for more resources. Last updated: 3/15/2010

MalaCards based summary : Follicular Lymphoma, also known as lymphoma, follicular, is related to follicular lymphoma 1 and nodal marginal zone b-cell lymphoma, and has symptoms including lymphedema, meningitis and splenomegaly. An important gene associated with Follicular Lymphoma is BCL10 (B Cell CLL/Lymphoma 10), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Arzerra and Intron A have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A B-cell lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has material basis in follicle center B-cells (centrocytes and centroblasts).

Wikipedia : 72 Follicular lymphoma is a type of blood cancer. It is the most common of the indolent (slow-growing)... more...

Related Diseases for Follicular Lymphoma

Diseases in the Follicular Lymphoma family:

Follicular Lymphoma 1

Diseases related to Follicular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 1 33.7 BCL10 BCL2 BCL6 FL1 IGH
2 nodal marginal zone b-cell lymphoma 31.7 BCL2 BCL6
3 primary effusion lymphoma 31.7 BCL6 IRF4 MYC
4 diffuse large b-cell lymphoma of the central nervous system 31.0 BCL2 MYC
5 intravascular large b-cell lymphoma 30.9 BCL2 BCL6 MME
6 lymphoma 30.9 BCL10 BCL2 BCL6 CCND1 KDSR MYC
7 primary mediastinal large b-cell lymphoma 30.8 BCL6 IRF4
8 burkitt lymphoma 30.8 AICDA BCL6 CD40 CR2 MS4A1 MYC
9 t-cell/histiocyte rich large b cell lymphoma 30.5 BCL6 CR2 IGH MME
10 mantle cell lymphoma 30.5 BCL2 BCL2L1 BCL6 CCND1 CD40 IGH
11 diffuse large b-cell lymphoma 30.5 BCL10 BCL6 CCND1 IRF4 MME MYC
12 lymphoma, hodgkin, classic 30.3 BCL6 CD40 IRF4 MS4A1
13 histiocytic sarcoma 30.3 BCL2 CR2 IGH MS4A1
14 primary cutaneous marginal zone b-cell lymphoma 30.2 BCL10 IRF4
15 angioimmunoblastic t-cell lymphoma 30.0 BCL6 MME
16 lymphoma, mucosa-associated lymphoid type 29.0 BCL10 BCL2 BCL6 CCND1 CD40 IGH
17 b-cell lymphomas 29.0 AICDA BCL10 BCL2 BCL2L1 BCL6 CCND1
18 marginal zone b-cell lymphoma 28.8 BCL10 BCL2 BCL6 CCND1 IRF4 MME
19 leukemia, chronic lymphocytic 27.5 AICDA BCL10 BCL2 BCL2L1 BCL6 CCND1
20 lymphoma, non-hodgkin, familial 26.4 AICDA BCL10 BCL2 BCL2L1 BCL6 CCND1
21 primary cutaneous follicle center lymphoma 11.4
22 histiocytic and dendritic cell cancer 11.0
23 gallbladder lymphoma 10.6 BCL6 MME
24 heart lymphoma 10.6 BCL6 MME
25 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.6 BCL2 BCL6 MYC
26 lymphoblastic lymphoma 10.5
27 lymphoma, small cleaved-cell, diffuse 10.5 BCL2 CCND1
28 precursor lymphoblastic lymphoma/leukemia 10.5 CD27 MME
29 immunodeficiency with hyper-igm, type 4 10.5 AICDA CD40
30 plasmablastic lymphoma 10.5
31 primary central nervous system lymphoma 10.5
32 acquired immunodeficiency syndrome 10.5 BCL6 FCGR3A MYC
33 immunodeficiency with hyper-igm, type 2 10.5 AICDA BCL6 CD40
34 testicular lymphoma 10.5 BCL6 MME
35 waldenstrom macroglobulinemia 10.4 BCL2 CD40 MS4A1
36 lymphoproliferative syndrome 2 10.4 BCL2L1 CD27 MCL1
37 nodular lymphocyte predominant hodgkin lymphoma 10.4 BCL6 CCND1
38 plasma cell leukemia 10.4 CCND1 IRF4
39 nervous system cancer 10.4 BCL2 CCND1 MYC
40 ovarian lymphoma 10.4 CR2 MME MYC
41 extramedullary plasmacytoma 10.3 BCL2 CCND1
42 gastrointestinal system cancer 10.3 BCL2L1 CCND1 MYC
43 mature b-cell neoplasm 10.3 AICDA BCL6 CD40 MME MYC
44 chops syndrome 10.3
45 hyperimmunoglobulin syndrome 10.2 AICDA CD40
46 immunodeficiency, common variable, 2 10.2 CR2 TNFRSF13C
47 leukemia, acute myeloid 10.2 BCL2L1 FCGR3A MCL1 MME MYC
48 lymphomatoid granulomatosis 10.2
49 leukemia 10.2
50 nasopharyngeal carcinoma 10.2 BCL2 BCL2L1 CCND1 MYC

Graphical network of the top 20 diseases related to Follicular Lymphoma:



Diseases related to Follicular Lymphoma

Symptoms & Phenotypes for Follicular Lymphoma

Human phenotypes related to Follicular Lymphoma:

31 (show all 12)
# Description HPO Frequency HPO Source Accession
1 lymphedema 31 occasional (7.5%) HP:0001004
2 meningitis 31 occasional (7.5%) HP:0001287
3 splenomegaly 31 frequent (33%) HP:0001744
4 weight loss 31 hallmark (90%) HP:0001824
5 fever 31 hallmark (90%) HP:0001945
6 pleural effusion 31 occasional (7.5%) HP:0002202
7 abnormality of the peritoneum 31 occasional (7.5%) HP:0002585
8 lymphoma 31 hallmark (90%) HP:0002665
9 fatigue 31 frequent (33%) HP:0012378
10 night sweats 31 hallmark (90%) HP:0030166
11 mediastinal lymphadenopathy 31 hallmark (90%) HP:0100721
12 skin nodule 31 occasional (7.5%) HP:0200036

GenomeRNAi Phenotypes related to Follicular Lymphoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 BCL10 BCL2 BCL2L1 MCL1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BCL10 BCL2 BCL2L1 CCND1 CD27 CD40

MGI Mouse Phenotypes related to Follicular Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.83 MCL1 MS4A1 MYC TNFRSF13C ZC3H12D AICDA
2 immune system MP:0005387 9.53 AICDA BCL10 BCL2 BCL2L1 BCL6 CCND1

Drugs & Therapeutics for Follicular Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arzerra 17 45 OFATUMUMAB GlaxoSmithKline October 2009
2
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Zevalin 17 45 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002

Drugs for Follicular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 525)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
4
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 24356-66-9 21704 32326
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
6 Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
10 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
11 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
12 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
15 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
16
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
18
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
19
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
20
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
21
Chlorambucil Approved Phase 3 305-03-3 2708
22
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
24
Iodine Approved, Investigational Phase 3,Phase 1,Phase 2 7553-56-2 807
25
Pixantrone Approved, Investigational Phase 3,Phase 2,Phase 1 144510-96-3
26
Idarubicin Approved Phase 3 58957-92-9 42890
27
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
28
Amoxicillin Approved, Vet_approved Phase 3,Phase 2 26787-78-0 33613 2171
29
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
30
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
33
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
34
Ofloxacin Approved Phase 3 82419-36-1 4583
35
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
36
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 460612 4053
37
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
38
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
39
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
40
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
41
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
42
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
43
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
44
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
45
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
46
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
47
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
48
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
49
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
50
Teniposide Approved Phase 3,Phase 1,Phase 2 29767-20-2 34698

Interventional clinical trials:

(show top 50) (show all 1126)

# Name Status NCT ID Phase Drugs
1 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
2 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 Low Grade Lymphoma Recruiting NCT01698866 Phase 4
5 A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients Unknown status NCT01303887 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Prednisolone;Fludarabine
6 Multicentric Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Patients With Stage II−IV Follicular Lymphoma Unknown status NCT00774826 Phase 3 R-CVP;R-CHOP;R-FM
7 Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma Unknown status NCT00435955 Phase 3 Rituximab
8 Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma Unknown status NCT00028691 Phase 3 chlorambucil
9 Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma Unknown status NCT00091676 Phase 3
10 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
11 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
12 Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
13 A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
14 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
15 Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
16 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
17 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
18 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
19 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
20 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
21 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
22 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
23 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
24 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
25 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
26 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
27 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
28 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
29 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
30 High-Dose Therapy Treatment in Patients With Follicular Lymphoma Completed NCT00696735 Phase 3
31 A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma Completed NCT02569996 Phase 3 Rituximab
32 Randomized Study for Patients With Follicular Lymphoma Needing Treatment Completed NCT00140569 Phase 3 fludarabine
33 GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma Completed NCT01419665 Phase 3
34 Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden Completed NCT00136552 Phase 3 rituximab
35 Primary Rituximab and Maintenance Completed NCT00140582 Phase 3 Rituximab
36 Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma Completed NCT00227695 Phase 3
37 Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy Completed NCT00185393 Phase 3
38 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
39 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
40 A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) Completed NCT01144364 Phase 3 rituximab [Mabthera/Rituxan]
41 Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma Completed NCT00310167 Phase 3
42 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed NCT00005589 Phase 3 carmustine;cyclophosphamide;cytarabine;etoposide;melphalan
43 Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Completed NCT00268983 Phase 3
44 MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Mabthera/Rituxan During First-Line Treatment for Lymphoma. Completed NCT01987505 Phase 3 rituximab [MabThera/Rituxan]
45 Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) Completed NCT00168740 Phase 3 rituximab
46 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed NCT00004179 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
47 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
48 Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients Completed NCT00577993 Phase 3 Fludarabine;Novantrone;Decadron;Rituximab;Interferon;Doxorubicin;Vincristine;Bleomycin;Cyclophosphamide;Etoposide;Cisplatin;Ara-C;Methyl-Prednisolone;Procarbazine;Prednisone
49 Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
50 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab

Search NIH Clinical Center for Follicular Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Follicular Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, follicular

Genetic Tests for Follicular Lymphoma

Genetic tests related to Follicular Lymphoma:

# Genetic test Affiliating Genes
1 Follicular Lymphoma 28

Anatomical Context for Follicular Lymphoma

MalaCards organs/tissues related to Follicular Lymphoma:

38
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Liver, Kidney

Publications for Follicular Lymphoma

Articles related to Follicular Lymphoma:

(show top 50) (show all 1005)
# Title Authors Year
1
Two for One: B-Cell Lymphomas with Features of Marginal and Follicular Lymphomas. ( 29408811 )
2018
2
Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. ( 29424927 )
2018
3
From genetics to the clinic: a translational perspective on follicular lymphoma. ( 29422597 )
2018
4
Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee. ( 29377067 )
2018
5
Follicular lymphoma: 2018 update on diagnosis and management. ( 29314206 )
2018
6
Clinical management and outcomes of completely resected stage I follicular lymphoma. ( 29415976 )
2018
7
Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-I+ induces prolonged clinical and molecular remissions in patients with follicular lymphoma. ( 29380359 )
2018
8
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. ( 29362504 )
2018
9
The combination of TRAIL and MG-132 induces apoptosis in both TRAIL-sensitive and TRAIL-resistant human follicular lymphoma cells. ( 29407584 )
2018
10
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. ( 29317554 )
2018
11
A leukemic double-hit follicular lymphoma associated with a complex variant translocation, t(8;14;18)(q24;q32;q21), involving BCL2, MYC, and IGH. ( 29310838 )
2018
12
Gastrointestinal follicular lymphoma: Current knowledge and future challenges. ( 29292593 )
2018
13
A watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma. ( 29377265 )
2018
14
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus<sup>131</sup>I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. ( 29356608 )
2018
15
Consolidation and maintenance in follicular lymphoma: radioimmunotherapy revisited? ( 29396095 )
2018
16
Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma. ( 29416725 )
2018
17
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. ( 29396094 )
2018
18
The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. ( 29318369 )
2018
19
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. ( 29390097 )
2018
20
Low grade follicular lymphoma extraparotid associated with primary SjAPgren's syndrome. ( 28865918 )
2017
21
Paraneoplastic acrokeratosis (Bazex syndrome): unusual association with in situ follicular lymphoma and response to acitretin. ( 28961299 )
2017
22
18F-Fluorodeoxyglucose positron emission tomography computed tomography detection threshold in follicular lymphoma: A case report. ( 29381956 )
2017
23
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. ( 28232365 )
2017
24
The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. ( 28060738 )
2017
25
Primary splenic low-grade follicular lymphoma presenting with leukaemia and large cell transformation in the marrow. ( 28826834 )
2017
26
Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. ( 28533310 )
2017
27
Extrafollicular PD1 and Intrafollicular CD3 Expression Are Associated With Survival in Follicular Lymphoma. ( 28733197 )
2017
28
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. ( 28782811 )
2017
29
Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting. ( 28824637 )
2017
30
Predicting transformation of follicular lymphoma. ( 28729342 )
2017
31
Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. ( 28841207 )
2017
32
High grade follicular lymphoma in a patient receiving adalimumab and methotrexate for pityriasis rubra pilaris. ( 28266882 )
2017
33
Fungating groin mass in a woman with a history of follicular lymphoma. ( 28814600 )
2017
34
T follicular helper cells: a potential therapeutic target in follicular lymphoma. ( 29340116 )
2017
35
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. ( 28771675 )
2017
36
IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. ( 28202459 )
2017
37
Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells. ( 28689633 )
2017
38
MYC expression and translocation analyses in low-grade and transformed Follicular Lymphoma. ( 28730642 )
2017
39
Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation? ( 28771060 )
2017
40
Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma. ( 28369180 )
2017
41
Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing. ( 28824170 )
2017
42
Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. ( 28413914 )
2017
43
Follicular Lymphoma with Hyaline-vascular Castleman-like Features Analysis of 6 Cases and Review of the Literature. ( 28873356 )
2017
44
Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. ( 28789937 )
2017
45
Recommendations for Clinical Trial Development in Follicular Lymphoma. ( 28040699 )
2017
46
Metachronous presentation of small-cell rectal carcinoma on an 18F-FDG PET/CT follow-up for follicular lymphoma. ( 28828141 )
2017
47
Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy. ( 28842137 )
2017
48
The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. ( 28784599 )
2017
49
Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. ( 27977511 )
2017
50
Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma. ( 28765546 )
2017

Variations for Follicular Lymphoma

ClinVar genetic disease variations for Follicular Lymphoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.427_428dupTT (p.Glu145Leufs) duplication Pathogenic rs587776632 GRCh37 Chromosome 1, 85733584: 85733585
2 BCL10 NM_003921.4(BCL10): c.231dupA (p.Gly78Argfs) duplication Pathogenic rs587776633 GRCh37 Chromosome 1, 85736416: 85736416
3 BCL10 NM_003921.4(BCL10): c.525_541del17 (p.Val176Asnfs) deletion Pathogenic rs587776634 GRCh37 Chromosome 1, 85733471: 85733487
4 BCL10 NM_003921.4(BCL10): c.410delA (p.Asn137Ilefs) deletion Pathogenic rs587776635 GRCh37 Chromosome 1, 85733602: 85733602
5 BCL10 NM_003921.4(BCL10): c.398dupT (p.Ser134Leufs) duplication Pathogenic rs587776636 GRCh37 Chromosome 1, 85733614: 85733614
6 BCL10 NM_003921.4(BCL10): c.635_637delAAG (p.Glu212del) deletion Pathogenic rs587776637 GRCh37 Chromosome 1, 85733375: 85733377

Cosmic variations for Follicular Lymphoma:

9 (show top 50) (show all 482)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43565 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.857A>G p.E286G 7
2 COSM44578 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.721T>C p.S241P 7
3 COSM10749 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.830G>T p.C277F 7
4 COSM6932 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.733G>A p.G245S 7
5 COSM44198 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.653T>G p.V218G 7
6 COSM44579 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.783T>G p.S261R 7
7 COSM44026 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.559G>A p.G187S 7
8 COSM44459 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.777C>A p.D259E 7
9 COSM100055 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.4256C>G p.P1419R 7
10 COSM36143 SOCS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.127C>T p.P43S 7
11 COSM36144 SOCS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.347G>A p.S116N 7
12 COSM563 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.34G>A p.G12S 7
13 COSM37031 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1936T>A p.Y646N 7
14 COSM37028 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1937A>T p.Y646F 7
15 COSM37032 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1937A>G p.Y646C 7
16 COSM37033 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1920T>A p.N640K 7
17 COSM24634 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.7848G>T p.M2616I 7
18 COSM21825 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1229T>C p.V410A 7
19 COSM24635 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.6067G>A p.G2023R 7
20 COSM83884 ARID1A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.3826C>T p.R1276* 7
21 COSM3733325 ZNF296 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.488G>A p.G163D 2
22 COSM3733324 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6190G>A p.E2064K 2
23 COSM3733267 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8147C>G p.S2716* 2
24 COSM10654 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.637C>T p.R213* 2
25 COSM43956 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.700T>A p.Y234N 2
26 COSM10656 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,mantle cell lymphoma c.742C>T p.R248W 2
27 COSM6901 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.559+1G>A p.? 2
28 COSM43848 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.472C>T p.R158C 2
29 COSM44687 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.379T>C p.S127P 2
30 COSM44972 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.831T>A p.C277* 2
31 COSM43846 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.487T>C p.Y163H 2
32 COSM10834 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.711G>A p.M237I 2
33 COSM10662 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.743G>A p.R248Q 2
34 COSM43833 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.578A>C p.H193P 2
35 COSM44692 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.526T>G p.C176G 2
36 COSM45626 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.501G>T p.Q167H 2
37 COSM10786 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.949C>T p.Q317* 2
38 COSM44843 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,MALT lymphoma c.759C>T p.T253T 2
39 COSM45773 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.583A>C p.I195L 2
40 COSM43901 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.421T>C p.C141R 2
41 COSM11564 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.742C>G p.R248G 2
42 COSM11059 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.713G>A p.C238Y 2
43 COSM10883 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.731G>A p.G244D 2
44 COSM45780 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.429G>T p.V143V 2
45 COSM44463 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.848G>T p.R283L 2
46 COSM11114 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.528C>G p.C176W 2
47 COSM10991 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.396G>T p.K132N 2
48 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.817C>T p.R273C 2
49 COSM43967 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.751A>T p.I251F 2
50 COSM44844 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,MALT lymphoma c.727A>G p.M243V 2

Copy number variations for Follicular Lymphoma from CNVD:

7 (show top 50) (show all 76)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13361 1 1 12700000 Copy number Follicular lymphoma
2 13749 1 1 27800000 Loss Follicular lymphoma
3 15761 1 119415209 120497765 Amplification NOTCH2 Follicular lymphoma
4 17512 1 143222462 153482569 Copy number ADAM15 Follicular lymphoma
5 17513 1 143222462 153482569 Copy number BCL9 Follicular lymphoma
6 17514 1 143222462 153482569 Copy number IL6R Follicular lymphoma
7 17515 1 143222462 153482569 Copy number MCL1 Follicular lymphoma
8 17516 1 143222462 153482569 Copy number PIAS3 Follicular lymphoma
9 17517 1 143222462 153482569 Copy number TNFAIP8L2 Follicular lymphoma
10 20608 1 153300000 154800000 Gain Follicular lymphoma
11 21393 1 158419998 161795584 Copy number DDR2 Follicular lymphoma
12 21394 1 158419998 161795584 Copy number PEX19 Follicular lymphoma
13 21395 1 158419998 161795584 Copy number UHMK1 Follicular lymphoma
14 25231 1 185800000 214500000 Gain Follicular lymphoma
15 54389 11 43400000 52900000 Gain Follicular lymphoma
16 61270 11 97200000 110400000 Gain Follicular lymphoma
17 65472 12 18053500 31175376 Amplification KRAS Follicular lymphoma
18 65473 12 18053500 31175376 Amplification PIK3C2G Follicular lymphoma
19 65474 12 18053500 31175376 Amplification RASSF8 Follicular lymphoma
20 65475 12 18053500 31175376 Amplification RERGL Follicular lymphoma
21 65476 12 18053500 31175376 Amplification SSPN Follicular lymphoma
22 67780 12 44600000 56300000 Gain Follicular lymphoma
23 69831 12 56316396 72147648 Copy number CDK4 Follicular lymphoma
24 69832 12 56316396 72147648 Copy number DYRK2 Follicular lymphoma
25 69833 12 56316396 72147648 Copy number FRS2 Follicular lymphoma
26 69834 12 56316396 72147648 Copy number IL22 Follicular lymphoma
27 69835 12 56316396 72147648 Copy number MDM2 Follicular lymphoma
28 69836 12 56316396 72147648 Copy number OS9 Follicular lymphoma
29 69837 12 56316396 72147648 Copy number RAB21 Follicular lymphoma
30 69838 12 56316396 72147648 Copy number RAP1B Follicular lymphoma
31 69839 12 56316396 72147648 Copy number RASSF3 Follicular lymphoma
32 69840 12 56316396 72147648 Copy number TBK1 Follicular lymphoma
33 69841 12 56316396 72147648 Copy number TSPAN31 Follicular lymphoma
34 69842 12 56316396 72147648 Copy number WIF1 Follicular lymphoma
35 69843 12 56316396 72147648 Copy number YEATS4 Follicular lymphoma
36 71140 12 67700000 71500000 Gain Follicular lymphoma
37 74580 13 109100000 114142980 Loss Follicular lymphoma
38 79541 13 73300000 79000000 Gain Follicular lymphoma
39 88260 14 88900000 106368585 Loss Follicular lymphoma
40 88262 14 88900000 106368585 Translocation Follicular lymphoma
41 92360 15 40100000 102531392 Loss Follicular lymphoma
42 97239 16 1 16700000 Gain Follicular lymphoma
43 106783 17 1 22200000 Deletion Follicular lymphoma
44 106829 17 1 24000000 Loss Follicular lymphoma
45 107553 17 15900000 22200000 Gain Follicular lymphoma
46 111280 17 35400000 47600000 Gain Follicular lymphoma
47 118113 17 7571720 7590868 Mutation P53 Follicular lymphoma
48 119191 18 1 59800000 Gain Follicular lymphoma
49 120855 18 33040900 33600413 Amplification BRUNOL4 Follicular lymphoma
50 121287 18 41800000 59800000 Translocation Follicular lymphoma

Expression for Follicular Lymphoma

LifeMap Discovery
Genes differentially expressed in tissues of Follicular Lymphoma patients vs. healthy controls: 35 (show top 50) (show all 56)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FCRLA Fc receptor-like A Intestine + 6.40 0.000
2 SERPINA9 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 Intestine + 5.98 0.000
3 VPREB3 pre-B lymphocyte 3 Intestine + 5.82 0.000
4 STAG3 stromal antigen 3 Intestine + 5.61 0.000
5 SNX22 sorting nexin 22 Intestine + 5.59 0.000
6 NLRP4 NLR family, pyrin domain containing 4 Intestine + 4.89 0.004
7 LTF lactotransferrin Intestine + 4.72 0.001
8 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) Intestine + 4.70 0.000
9 AIM2 absent in melanoma 2 Intestine + 4.66 0.000
10 P2RX5 purinergic receptor P2X, ligand gated ion channel, 5 Intestine + 4.54 0.000
11 BFSP2 beaded filament structural protein 2, phakinin Intestine + 4.33 0.000
12 DOK7 docking protein 7 Intestine + 4.29 0.000
13 KLHL14 kelch-like family member 14 Intestine + 4.26 0.000
14 GPR18 G protein-coupled receptor 18 Intestine + 4.26 0.000
15 PAX5 paired box 5 Intestine + 4.21 0.000
16 CNR1 cannabinoid receptor 1 (brain) Intestine + 4.15 0.001
17 PMCH pro-melanin-concentrating hormone Intestine + 4.09 0.000
18 AFF3 AF4/FMR2 family, member 3 Intestine + 4.02 0.000
19 MMP12 matrix metallopeptidase 12 Intestine + 3.94 0.001
20 LOC613266 uncharacterized LOC613266 Intestine + 3.92 0.000
21 C17orf99 chromosome 17 open reading frame 99 Intestine + 3.88 0.003
22 PCDHGB3 protocadherin gamma subfamily B, 3 Intestine + 3.82 0.002
23 TMEM156 transmembrane protein 156 Intestine + 3.81 0.000
24 FCRL2 Fc receptor-like 2 Intestine + 3.76 0.001
25 SCIMP SLP adaptor and CSK interacting membrane protein Intestine + 3.75 0.000
26 CCL17 chemokine (C-C motif) ligand 17 Intestine + 3.73 0.004
27 VNN2 vanin 2 Intestine + 3.71 0.000
28 OR13A1 olfactory receptor, family 13, subfamily A, member 1 Intestine + 3.59 0.001
29 PCDHGB2 protocadherin gamma subfamily B, 2 Intestine + 3.53 0.001
30 CYP4F11 cytochrome P450, family 4, subfamily F, polypeptide 11 Intestine - 3.53 0.015
31 APOBEC2 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 Intestine - 3.51 0.003
32 KIAA1549L KIAA1549-like Intestine + 3.45 0.003
33 TCL6 T-cell leukemia/lymphoma 6 (non-protein coding) Intestine + 3.41 0.005
34 AFF2 AF4/FMR2 family, member 2 Intestine + 3.35 0.006
35 CD37 CD37 molecule Intestine + 3.24 0.000
36 IL22RA2 interleukin 22 receptor, alpha 2 Intestine + 3.22 0.012
37 ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 Intestine + 3.22 0.001
38 ARHGAP24 Rho GTPase activating protein 24 Intestine + 3.21 0.001
39 PLEKHG7 pleckstrin homology domain containing, family G (with RhoGef domain) member 7 Intestine + 3.20 0.000
40 CAPN14 calpain 14 Intestine + 3.20 0.002
41 SPANXN3 SPANX family, member N3 Intestine - 3.18 0.002
42 TMEM155 transmembrane protein 155 Intestine + 3.16 0.002
43 RPS16P5 ribosomal protein S16 pseudogene 5 Intestine + 3.15 0.000
44 SLC7A10 solute carrier family 7 (neutral amino acid transporter light chain, asc system), member 10 Intestine + 3.15 0.002
45 SLC5A12 solute carrier family 5 (sodium/monocarboxylate cotransporter), member 12 Intestine - 3.13 0.000
46 PCDH11Y protocadherin 11 Y-linked Intestine + 3.13 0.001
47 BEND4 BEN domain containing 4 Intestine + 3.13 0.001
48 PCDHGA5 protocadherin gamma subfamily A, 5 Intestine + 3.12 0.006
49 MYBL1 v-myb avian myeloblastosis viral oncogene homolog-like 1 Intestine + 3.11 0.008
50 PDCD1 programmed cell death 1 Intestine + 3.09 0.001
Search GEO for disease gene expression data for Follicular Lymphoma.

Pathways for Follicular Lymphoma

Pathways related to Follicular Lymphoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 BCL10 BCL2 BCL2L1 BCL6 CCND1 CD27
2
Show member pathways
13.18 BCL2 BCL2L1 BCL6 CCND1 CD27 CD40
3
Show member pathways
12.74 BCL2 BCL2L1 CD27 IRF4 MCL1 MYC
4
Show member pathways
12.53 BCL2 BCL2L1 IRF4 MCL1 MYC
5 12.46 BCL2 CCND1 MCL1 MYC
6
Show member pathways
12.43 BCL2 BCL2L1 CCND1 MYC
7
Show member pathways
12.35 BCL2L1 CCND1 IGH MYC
8 12.34 BCL2L1 CCND1 CD40 MYC TNFRSF13C
9
Show member pathways
12.33 BCL2 BCL2L1 CR2 TNFRSF13C
10
Show member pathways
12.28 BCL10 BCL6 CR2 IRF4 MYC
11 12.25 BCL2 CD40 CR2 MYC
12
Show member pathways
12.21 BCL2 BCL2L1 CCND1 MCL1 MYC
13
Show member pathways
12.19 BCL2 BCL2L1 CD40 FCGR3A
14 12.18 BCL2L1 BCL6 CD40 MYC
15
Show member pathways
12.17 BCL2 BCL2L1 CCND1 MYC
16 12.12 BCL10 BCL2 BCL2L1 MCL1 MYC
17 11.91 BCL2 BCL6 CCND1 MYC
18
Show member pathways
11.84 BCL2 BCL2L1 MYC
19 11.84 CR2 MME MS4A1
20
Show member pathways
11.78 BCL2L1 MCL1 MYC
21
Show member pathways
11.77 BCL2 BCL2L1 MCL1
22 11.76 BCL2 BCL2L1 CCND1 MYC
23
Show member pathways
11.75 CD27 CD40 TNFRSF13C
24 11.73 BCL2 CCND1 MYC
25 11.7 IRF4 MME MS4A1
26 11.7 BCL10 BCL2 BCL2L1 CD40 TNFRSF13C
27
Show member pathways
11.69 BCL2 BCL2L1 CD40
28
Show member pathways
11.64 BCL2 BCL2L1 MYC
29 11.61 AICDA BCL6 IRF4
30 11.58 BCL2 CCND1 MYC
31 11.49 BCL2L1 CCND1 MYC
32
Show member pathways
11.41 BCL2 BCL2L1 MYC
33 11.41 BCL2 BCL2L1 CCND1 MCL1
34
Show member pathways
11.4 BCL2L1 CCND1 MYC
35
Show member pathways
11.38 BCL2 BCL2L1 MCL1
36 11.37 BCL6 CD40 CR2 FCGR3A TNFRSF13C
37 11.32 AICDA CD40 TNFRSF13C
38 11.29 BCL2L1 CCND1 MYC
39 11.22 BCL2 BCL2L1 BCL6 CCND1 IRF4 MCL1
40 11.16 BCL6 CD27 CD40 CR2 MME MS4A1
41 11 BCL2 BCL2L1 MCL1

GO Terms for Follicular Lymphoma

Cellular components related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 CD27 CD40 FCGR3A MS4A1 TNFRSF13C
2 Bcl-2 family protein complex GO:0097136 8.96 BCL2L1 MCL1

Biological processes related to Follicular Lymphoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.96 BCL10 BCL6 CD40 CR2 TNFRSF13C
2 negative regulation of apoptotic process GO:0043066 9.88 BCL2 BCL2L1 BCL6 CD27 MCL1 MYC
3 regulation of apoptotic process GO:0042981 9.85 BCL10 BCL2 BCL2L1 BCL6 MCL1
4 regulation of immune response GO:0050776 9.84 BCL6 CD40 FCGR3A TNFRSF13C
5 response to cytokine GO:0034097 9.7 BCL2 BCL2L1 MCL1
6 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.67 BCL2 BCL2L1 MCL1
7 ovarian follicle development GO:0001541 9.65 BCL2 BCL2L1 MYC
8 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.61 BCL2 BCL2L1 MCL1
9 negative regulation of anoikis GO:2000811 9.58 BCL2 MCL1